213 related articles for article (PubMed ID: 29324547)
1. Stereotactic Body Radiation Therapy, Intensity-Modulated Radiation Therapy, and Brachytherapy Boost Modalities in Invasive Cervical Cancer: A Study of the National Cancer Data Base.
OʼDonnell B; Shiao JC; Pezzi TA; Waheed N; Sharma S; Bonnen MD; Ludwig MS
Int J Gynecol Cancer; 2018 Mar; 28(3):563-574. PubMed ID: 29324547
[TBL] [Abstract][Full Text] [Related]
2. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements.
Gill BS; Lin JF; Krivak TC; Sukumvanich P; Laskey RA; Ross MS; Lesnock JL; Beriwal S
Int J Radiat Oncol Biol Phys; 2014 Dec; 90(5):1083-90. PubMed ID: 25216857
[TBL] [Abstract][Full Text] [Related]
3. Outcomes for patients with locally advanced pancreatic adenocarcinoma treated with stereotactic body radiation therapy versus conventionally fractionated radiation.
Zhong J; Patel K; Switchenko J; Cassidy RJ; Hall WA; Gillespie T; Patel PR; Kooby D; Landry J
Cancer; 2017 Sep; 123(18):3486-3493. PubMed ID: 28493288
[TBL] [Abstract][Full Text] [Related]
4. Is SBRT Boost Feasible for PET Positive Lymph Nodes for Cervical Cancer? Evaluation using Tumor Control Probability and QUANTEC Criteria.
Snyder JE; Willett AB; Sun W; Kim Y
Pract Radiat Oncol; 2019 Mar; 9(2):e156-e163. PubMed ID: 30415074
[TBL] [Abstract][Full Text] [Related]
5. Why brachytherapy boost is the treatment of choice for most women with locally advanced cervical carcinoma?
Al Feghali KA; Elshaikh MA
Brachytherapy; 2016; 15(2):191-9. PubMed ID: 26810408
[TBL] [Abstract][Full Text] [Related]
6. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer.
Assenholt MS; Vestergaard A; Kallehauge JF; Mohamed S; Nielsen SK; Petersen JB; Fokdal L; Lindegaard JC; Tanderup K
Brachytherapy; 2014; 13(4):361-8. PubMed ID: 24656732
[TBL] [Abstract][Full Text] [Related]
7. Brachytherapy: A critical component of primary radiation therapy for cervical cancer: From the Society of Gynecologic Oncology (SGO) and the American Brachytherapy Society (ABS).
Holschneider CH; Petereit DG; Chu C; Hsu IC; Ioffe YJ; Klopp AH; Pothuri B; Chen LM; Yashar C
Gynecol Oncol; 2019 Mar; 152(3):540-547. PubMed ID: 30665615
[TBL] [Abstract][Full Text] [Related]
8. The early adoption of intensity-modulated radiotherapy and stereotactic body radiation treatment among older Medicare beneficiaries with prostate cancer.
Jacobs BL; Yabes JG; Lopa SH; Heron DE; Chang CH; Schroeck FR; Bekelman JE; Kahn JM; Nelson JB; Barnato AE
Cancer; 2017 Aug; 123(15):2945-2954. PubMed ID: 28301689
[TBL] [Abstract][Full Text] [Related]
9. Impact of marital status on receipt of brachytherapy and survival outcomes in locally advanced cervical cancer.
Huynh-Le MP; Klapheke A; Cress R; Mell LK; Yashar CM; Einck JP; Mundt AJ; Mayadev JS
Brachytherapy; 2019; 18(5):612-619. PubMed ID: 31153760
[TBL] [Abstract][Full Text] [Related]
10. Stereotactic body radiotherapy for unresected pancreatic cancer: A nationwide review.
de Geus SWL; Eskander MF; Kasumova GG; Ng SC; Kent TS; Mancias JD; Callery MP; Mahadevan A; Tseng JF
Cancer; 2017 Nov; 123(21):4158-4167. PubMed ID: 28708929
[TBL] [Abstract][Full Text] [Related]
11. Brachytherapy Boost Utilization and Survival in Unfavorable-risk Prostate Cancer.
Johnson SB; Lester-Coll NH; Kelly JR; Kann BH; Yu JB; Nath SK
Eur Urol; 2017 Nov; 72(5):738-744. PubMed ID: 28688613
[TBL] [Abstract][Full Text] [Related]
12. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
13. Evaluating Intensity-Modulated Radiation Therapy in Locally Advanced Non-Small-Cell Lung Cancer: Results From the National Cancer Data Base.
Jegadeesh N; Liu Y; Gillespie T; Fernandez F; Ramalingam S; Mikell J; Lipscomb J; Curran WJ; Higgins KA
Clin Lung Cancer; 2016 Sep; 17(5):398-405. PubMed ID: 26936682
[TBL] [Abstract][Full Text] [Related]
14. Brachytherapy Improves Survival in Stage III Endometrial Cancer With Cervical Involvement.
Bingham B; Orton A; Boothe D; Stoddard G; Huang YJ; Gaffney DK; Poppe MM
Int J Radiat Oncol Biol Phys; 2017 Apr; 97(5):1040-1050. PubMed ID: 28332987
[TBL] [Abstract][Full Text] [Related]
15. The prognostic factors for locally advanced cervical cancer patients treated by intensity-modulated radiation therapy with concurrent chemotherapy.
Chen CC; Wang L; Lin JC; Jan JS
J Formos Med Assoc; 2015 Mar; 114(3):231-7. PubMed ID: 25777974
[TBL] [Abstract][Full Text] [Related]
16. Intensity-modulated radiation therapy for advanced cervical cancer: a comparison of dosimetric and clinical outcomes with conventional radiotherapy.
Du XL; Tao J; Sheng XG; Lu CH; Yu H; Wang C; Song QQ; Li QS; Pan CX
Gynecol Oncol; 2012 Apr; 125(1):151-7. PubMed ID: 22198339
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of prostate boost with high-dose-rate brachytherapy versus intensity-modulated radiation therapy in the treatment of intermediate-high risk prostate cancer.
Vu CC; Blas KG; Lanni TB; Gustafson GS; Krauss DJ
Brachytherapy; 2018; 17(6):852-857. PubMed ID: 30076108
[TBL] [Abstract][Full Text] [Related]
18. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract][Full Text] [Related]
19. Survival Benefit of Adjuvant Brachytherapy After Hysterectomy With Positive Surgical Margins in Cervical Cancer.
Li R; Shinde A; Chen YJ; Amini A; Lee S; Dellinger T; Han E; Wakabayashi M; Nelson R; Beriwal S; Glaser S
Int J Radiat Oncol Biol Phys; 2018 Oct; 102(2):373-382. PubMed ID: 29890264
[TBL] [Abstract][Full Text] [Related]
20. [Application value of reduced field intensity modulated radiation therapy for advanced cervical cancer].
DU XL; Sheng XG; Wang C; Yu H; Song QQ; Pan CX
Zhonghua Zhong Liu Za Zhi; 2013 Dec; 35(12):925-31. PubMed ID: 24506963
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
